Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Regeneron | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Regeneron

Revenues up 22% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Regeneron
4Q Revenues: $1.9 billion (+22%)
4Q Earnings: $820 million (+371%)
FY Revenues: $6.7 billion (+14%)
FY Earnings: $ 2.4 billion (+104%)
Comments: EYLEA Injection sales in the U.S. increased 11% to $1.1 billion. EYLEA sales outside the U.S., which are recorded by the Company’s collaborator Bayer, increased 14% to $724 million in the quarter. Libtayo Injection sales in the U.S. were $15 million in the first three months of launch. Dupixent Injection global net sales, which are recorded by the Company’s collaborator Sanofi, were $319 million in the quarter. The Company’s effective tax rate for both the quarter and full year 2018 was significantly impacted by the U.S. Tax Reform Act, which reduced the U.S. federal corporate income tax rate from 35% to 21% effective January 1, 2018.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters